期刊文献+

2006年我院临床分离非发酵革兰阴性杆菌耐药性分析 被引量:2

下载PDF
导出
摘要 目的了解2006年我院临床分离非发酵革兰阴性杆菌的分布和耐药性。方法采用法国梅里埃公司ATB细菌鉴定仪鉴定,药敏试验为K-B纸片扩散法。结果铜绿假单胞菌对亚胺培南、头孢哌酮/舒巴坦、阿米卡星的耐药率均低于19%;鲍曼不动杆菌对亚胺培南的耐药率最低为4.5%,其次为头孢哌酮/舒巴坦8.3%;嗜麦芽窄食单胞菌对头孢哌酮/舒巴坦、替卡西林/克拉维酸、哌拉西林/三唑巴坦耐药率依次为0%、5.0%和10.0%。结论非发酵革兰阴性杆菌的分离率、耐药性有升高趋势,应根据药敏试验结果选用抗菌药物。
出处 《江西医学检验》 2007年第3期243-244,共2页 Jiangxi Journal of Medical Laboratory Sciences
  • 相关文献

参考文献7

  • 1Murray PR,Bamn EJ,Pfaller MA,et al.Manual of clinical microbiology[M].7th Edition.Washington DC:American Society for Microbiology,1999,552-554.
  • 2Quinn JP.Clinical problem posed by multiresistant nonfermenting gram-negative pathogens[J].Clin Infect Dis,1998,27(Suppl 1):S117-124.
  • 3王美琴,蒋金芬,来汉江,李毅本.非发酵菌鉴定及耐药性分析[J].中国公共卫生,2002,18(7):822-823. 被引量:46
  • 4罗百灵,王丽静,胡成平,戴文鑫.1995-2004年下呼吸道感染病原菌变迁[J].中国感染与化疗杂志,2006,6(3):182-185. 被引量:34
  • 5颜秉兴.465株非发酵菌耐药分析[J].江西医学检验,2004,22(5):433-434. 被引量:2
  • 6Fernandez-Cuenca F,Maninez-Maninez L,Conejo MC,et al.Relationship between beta-lactamase production,outer membrance protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii[J].J Antimicrob Chemother.2003.51:565-574.
  • 7Walsh TR,MacGowan AP,Bennett PM.Sequence analysis and enzyme Kinetics of the L-serine beta-lactamase from Stenotrophomonas maltophilia[J].Antirnicrob Agents chemother,1997,41(7):1460-1463.

二级参考文献19

  • 1党斌温,张杰,邵丽丽,唐明忠.呼吸病房院内下呼吸道感染细菌及其耐药性的变迁[J].首都医科大学学报,2004,25(3):353-355. 被引量:15
  • 2刘振声 金大鹏.医院感染管理,第1版[M].北京:军事医学科学出版社,2000.84.
  • 3叶应抚 王毓三.微生物检验.全国临床检验操作规程[M].北京:中华人民卫共和国卫生部医司,1997.1.
  • 4National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing[S]. Tenth informational supplement M 100-S1 3,2003.
  • 5Segatore B, Setacci D, Perilli M, et al. Italian Survey on Comparative Levofloxacin Susceptibility in 334 Clinical Isolates of Pseudomonas aeruginosa [J]. Antimicrobial Agents and Chemotherapy,1999, 43(2):428~43 1.
  • 6Segatore B, Setacci D, Perilli M, et al. Italian survey on comparative levofloxacin suscptibility in 334 clinical isolates of Psoudomonas aeruginosa[J]. Antimicrobial Agents and Chemotherapy, 1999,43(2):428~431.
  • 7Gesu GP, Marchetti F, Piccoli L, et al. Levofloxacin and Ciprofloxacin In Vitro Activities against 4,003 Clinical Bacterial Isolates Collected in 24 Italian Laboratories[J]. Antimicrobial Agents and Chemotherapy, 2003, 47(2):816~819.
  • 8Betriu C, Rodriguez-Avial I, Sanchez BA, et al. In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain[J]. Antimicrobial Agents and Chemotherapy. 2002, 46(3):892~895.
  • 9Yong D, Lee K, Yum JH, et al. Imipenem-EDTA Disk Method for Differentiation of Metallo β-Lactamase-Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp[J]. Journal of Clinical Microbiology, 2002,40(10):3798~3801.
  • 10Felmingham D,Gruneberg RN. The Alexander Project 1996 -1997 :latest susceptibility data from this international study of bacterial pathogens from community acquired lower respiratory tract infections[J]. J Antimicrob Chemother,2000,45:191-203.

共引文献77

同被引文献10

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部